16 To 24 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.4)
-
Patent number: 8828949Abstract: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides or conjugates. The present invention also relates to the use of these polypeptides for transporting a compound or drug across the blood-brain barrier of a mammal and in the treatment and diagnosis of neurological diseases.Type: GrantFiled: March 7, 2011Date of Patent: September 9, 2014Assignee: Angiochem, Inc.Inventors: Richard Beliveau, Michel Demeule, Christian Che, Anthony Regina
-
Patent number: 8828940Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.Type: GrantFiled: December 14, 2010Date of Patent: September 9, 2014Assignee: Compugen Ltd.Inventors: Yossi Cohen, Ronen Shemesh, Amir Toporik, Zurit Levine, Assaf Wool, Dvir Dahary, Iris Hecht, Galit Rotman, Michal Ayalon-Soffer
-
Patent number: 8822423Abstract: We have disclosed affinity peptides toward infliximab. More specifically we have disclosed an affinity biomatrix where the affinity peptide is covalently attached to a biocompatible, biodegradable polymer. The affinity biomatrix is useful in preparing controlled release devices for infliximab.Type: GrantFiled: May 17, 2012Date of Patent: September 2, 2014Assignee: Janssen Biotech, Inc.Inventors: Daphne Ann Salick Ryan, John Kehoe, John Wheeler, Chunlin Yang, Abla Creasey
-
Publication number: 20140242123Abstract: The disclosure provides for saccharide-peptide based hydrogels, the functionalization of the saccharide-peptide based hydrogels with one or more biological agents, and the encapsulation of one or more biological materials and/or pharmaceutical agents in the hydrogels. The disclosure further provides for the use of the saccharide-peptide based hydrogels in treating a disease or disorder in a subject.Type: ApplicationFiled: February 21, 2014Publication date: August 28, 2014Inventors: Zhibin Guan, Yoko Mullen, Sophia W. Liao
-
Patent number: 8815813Abstract: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, as well as methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation in viral infection, are described. For example, polypeptides and other compounds can be used to inhibit binding of DF-associated, immune-complexed IgG anti-DF viron(s) or DV viral antigens to F?R, ADE of DF/DHF/DSS infections by inhibition of DF viral antigen binding to immune complexed IgG, F?R and immune complexed IgG mC1q (membrane C1q) or soluble C1q binding.Type: GrantFiled: July 17, 2009Date of Patent: August 26, 2014Assignee: Trinity Therapeutics, Inc.Inventor: Neil M. Bodie
-
Patent number: 8815812Abstract: The present invention relates to new arginine substituted peptides designed based on the sequence of human lactoferrin and to use thereof, in particular for treatment and/or prevention of infections, inflammations, tumors, pain, wounds and/or scars.Type: GrantFiled: April 19, 2011Date of Patent: August 26, 2014Assignee: Inger Mattsby-BaltzerInventors: Inger Mattsby-Baltzer, Gunnar Dolphin
-
Publication number: 20140235557Abstract: The invention relates to small cell penetrating peptides (CPP) derived from the scorpion toxin maurocalcine and to their use as vectors for the intracellular delivery of various drugs and agents.Type: ApplicationFiled: June 20, 2012Publication date: August 21, 2014Applicants: Commissariat A L'Energie Atomique Et Aux Energies Alternatives, Universite Joseph Fourier, Institut National De La Sante Et De La Recherche Medicale (INSERM)Inventor: Michel De Waard
-
Publication number: 20140234334Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO: 104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO: 105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18 (SEQ. ID. NO: 107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO: 109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.Type: ApplicationFiled: July 9, 2013Publication date: August 21, 2014Applicant: AMGEN INC.Inventors: Hosung MIN, Hailing HSU, Fei XIONG
-
Publication number: 20140235544Abstract: The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.Type: ApplicationFiled: February 15, 2013Publication date: August 21, 2014Inventor: Yitzchak Hillman
-
Patent number: 8809275Abstract: Provided herein are peptoids capable of inhibiting or reversing amyloid ? (A?) fibril or plaque production. The peptoids form a helical structure with three monomers per helical turn and have at least two monomers with a side-chain having an arylalkyl group having the same chirality positioned such that the side-chains are on the same side of the peptoid. Also provided are methods of using the peptoids to inhibit or reverse aggregation of A? and methods of treating subjects with Alzheimer's disease (AD) or slowing the progression of AD.Type: GrantFiled: October 19, 2012Date of Patent: August 19, 2014Assignees: The Board of Trustees of the University of Arkansas, University of South CarolinaInventors: Shannon Servoss, Melissa Moss
-
Publication number: 20140228276Abstract: The present invention relates to the ability of PLUNC proteins, such as SPLUNC1 and SPLUNC2, to bind to sodium channels and inhibit activation of the sodium channels. The invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by modulating the binding of PLUNC proteins to sodium channels.Type: ApplicationFiled: September 19, 2012Publication date: August 14, 2014Applicant: The University of North Carolina at Chapel HillInventors: Robert Tarran, Monroe Jack Stutts, Scott Donaldson
-
Publication number: 20140227279Abstract: Compositions and methods for the treatment of autoimmune and inflammatory diseases are disclosed.Type: ApplicationFiled: August 9, 2012Publication date: August 14, 2014Applicant: Lankenau Institute for Medical ResearchInventors: Lisa Laury-Kleintop, Laura Mandik-Nayak, George C. Prendergast, James Duhadaway
-
Patent number: 8802634Abstract: The present invention provides compositions comprising peptidyl inhibitors of CD40L-dependent signalling that are not derived from a natural binding partner of CD40L such as CD40, or from a native CD40-CD40L interface. More particularly, the peptidyl inhibitors of the present invention are derived from natural sources that do not express CD40-CD40L costimulatory pathways. The invention also provides synthetic derivatives and analogs of the peptidyl inhibitors having enhanced binding affinity for CD40L or enhanced inhibitory activity relative to their parent molecules.Type: GrantFiled: July 13, 2009Date of Patent: August 12, 2014Assignee: Phylogica LimitedInventors: Paul Michael Watt, Richard Hopkins, Katrin Hoffman
-
Publication number: 20140220070Abstract: The present invention relates to the use of a composition comprising at least one cell membrane fraction or parts thereof, for the reduction of lipolytic activity and/or to retard fat digestion, suppress appetite, body weight and/or lower blood lipids. The invention also relates to the use of said hydrophobic peptide in a pharmaceutical as well as a food composition and methods of treating a mammal with said composition.Type: ApplicationFiled: December 23, 2013Publication date: August 7, 2014Applicant: Thylabisco ABInventors: Per-Ake ALBERTSSON, Charlotte ERLANSSON-ALBERTSSON
-
Publication number: 20140219979Abstract: The present invention provides novel uses for peptide p277—positions 437-460 of human heat shock protein 60 (HSP60)—in modulation of immune responses and inflammatory diseases. The invention further provides novel uses for HSP60 and p277 in the treatment or prevention of hepatic disorders. The invention discloses methods for treating, preventing or ameliorating the symptoms of T cell mediated inflammatory and autoimmune disorders, including hepatic disorders, which comprise administering to a subject in need thereof a composition comprising as an active ingredient an effective quantity of a molecule selected from: HSP60, p277, fragments, analogs, homologs and derivatives thereof, and nucleic acids encoding same. Also disclosed are T cell vaccination methods for treating or preventing T cell mediated disorders.Type: ApplicationFiled: March 21, 2014Publication date: August 7, 2014Applicant: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Alexandra Zanin-Zhorov, Guy Tal, Francisco Quintana, Meirav Pisner, Ofer Lider
-
Publication number: 20140221296Abstract: The invention is directed to methods for extracting phosvitin from egg yolk involving contacting the egg yolk or egg yolk protein granules with a solution having a salt concentration of about 10% to form a mixture; optionally, heating the mixture; adjusting the pH of the mixture to separate phosvitin from other proteins; recovering the phosvitin. The phosvitin extract may be dephosphorylated and hydrolyzed to produce phosvitin phosphopeptides.Type: ApplicationFiled: June 11, 2012Publication date: August 7, 2014Applicant: THE GOVERNORS OF THE UNIVERSITY OF ALBERTAInventors: Jianping Wu, Bo Lei, Jiandong Ren
-
Publication number: 20140219981Abstract: The present invention relates in general to the field of tissue engineering and more specifically to amphiphilic peptides and peptide matrices thereof useful in vitro and in situ biomineralization and inducing bone repair. The present invention provides peptides, which are useful in hydrogels and other pharmaceutical compositions, and methods and kits of use for bone repair and promotion of biomineralization. Certain hydrogels according to the invention comprise cells within or adhered to the peptide matrix.Type: ApplicationFiled: January 14, 2014Publication date: August 7, 2014Applicant: Ben-Gurion University of the Negev Research and Development AuthorityInventor: Hanna RAPAPORT
-
Patent number: 8796416Abstract: Provided herein are methods for prophylactic treatment of renal disorders comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual suspected of having, predisposed to, or at risk of developing a renal disorder.Type: GrantFiled: October 25, 2011Date of Patent: August 5, 2014Assignee: Questcor Pharmaceuticals, IncInventors: Steve Cartt, Rujun Gong
-
Patent number: 8796226Abstract: Long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer are provided. In particular, the long acting pharmaceutical composition comprises a therapeutically effective amount of glatiramer acetate in depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot form is suitable for subcutaneous or intramuscular implantation or injection.Type: GrantFiled: August 19, 2010Date of Patent: August 5, 2014Assignee: Mapi Pharma Ltd.Inventors: Ehud Marom, Shai Rubnov
-
Publication number: 20140213534Abstract: Compositions for and methods of preventing or reducing the severity intestinal hyperpermeabilization in an individual are disclosed. Compositions for and methods of preventing or reducing the severity of a disease or condition caused or exacerbated by intestinal hyperpermeabilization in an individual identified as being at risk of a disease or condition caused or exacerbated by intestinal hyperpermeabilization are also disclosed. Compositions for and methods of treating an individual who has been identified as having a disease or condition caused or exacerbated by intestinal hyperpermeabilization are additionally disclosed.Type: ApplicationFiled: April 27, 2012Publication date: July 31, 2014Applicant: Thomas Jefferson UniversityInventors: Scott A. Waldman, Adam E. Snook, Peng Li, Jieru Egeria Lin
-
Patent number: 8790653Abstract: The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides.Type: GrantFiled: November 1, 2011Date of Patent: July 29, 2014Assignee: Yeda Research and Development Co. Ltd.Inventors: Johannes Herkel, Irun R. Cohen, Varda Rotter, Ansgar W. Lohse, Neta Erez, Avishai Mimran, Na'aman Kam
-
Publication number: 20140206628Abstract: Polypeptides are disclosed herein, which recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection.Type: ApplicationFiled: March 21, 2014Publication date: July 24, 2014Applicant: University of Washington through its Center for CommercializationInventors: David BAKER, Timothy A. WHITEHEAD, Sarel FLEISHMAN
-
Publication number: 20140199325Abstract: The present invention provides a polypeptides capable of modulating tissue transglutarmnase-induced cell behaviour wherein the polypeptide comprises or consists of either (a) the amino acid sequence of a heparin-binding site of a tissue transglutaminase, or a functional fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof or (b) an antibody capable of binding to a heparin-binding site of a lissue transglutaminase, or an antigen-binding fragment or derivative thereof. In one embodiment, the heparin-binding site of a tissue transglutaminase comprises or consists of an amino acid sequence of SEQ ID NO: 1, The invention further provides medical uses of the polypeptides of the invention and methods of treatment using the same.Type: ApplicationFiled: April 30, 2012Publication date: July 17, 2014Applicant: AstonUniversityInventors: Russell Collighan, Martin Griffin, Kamila Pytel, Zhuo Wang
-
Publication number: 20140200187Abstract: The present invention refers to protein kinase inhibitors and more specifically to inhibitors of the protein kinase c-Jun amino terminal kinase. Additionally, the present invention provides JNK inhibitor sequences, chimeric peptides, nucleic acids encoding same as well as pharmaceutical compositions for treating pathophysiologies associated with JNK signaling.Type: ApplicationFiled: December 31, 2013Publication date: July 17, 2014Applicant: XIGEN INFLAMMATION LTD.Inventor: Christophe Bonny
-
Patent number: 8778303Abstract: The invention encompasses radiopharmaceutical compounds that can be used in imaging cell death associated with either apoptosis or necrosis. Phosphatidylethanolamine (PtdE) is externalized to the surface of apoptotic cells, and also becomes accessible in necrotic cells due to compromised plasma membrane integrity. Duramycin, a 19 amino acid polypeptide, binds PtdE at a 1:1 ratio with high affinity and exclusive specificity. Novel Duramycin-based radiopharmaceuticals and non-radioactively labeled compounds are disclosed herein. Such compounds facilitate detection of cell apoptosis and/or necrosis by binding to PtdE. The location of the bound compound can then be pinpointed using standard imaging techniques.Type: GrantFiled: January 10, 2011Date of Patent: July 15, 2014Assignee: The Medical College of Wisconsin, Inc.Inventor: Ming Zhao
-
Patent number: 8778886Abstract: A peptide-POD with ability to penetrate and deliver fluorophores, siRNA, DNA and quantum dots to cells in culture and retinal and ocular tissues in vivo is provided herein. POD couples to adenovirus vectors, enhancing tropism for certain cells, potentially providing a safer and more efficacious method to deliver molecules to ocular and other tissues in vivo. POD constructs are therapeutic delivery vehicles for treating cells and tissues, including ocular cells and tissues suffering from retinal degeneration.Type: GrantFiled: February 26, 2010Date of Patent: July 15, 2014Assignee: Tufts UniversityInventors: Rajendra Kumar-Singh, Siobhan M. Cashman, Sarah Parker Read
-
Publication number: 20140194358Abstract: Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration.Type: ApplicationFiled: October 28, 2013Publication date: July 10, 2014Applicant: Children's Medical Center CorporationInventors: Avner Adini, Robert D'Amato
-
Patent number: 8772229Abstract: The invention provides inhibitors of ghrelin O-acyltransferase, and methods of making and using them. In some embodiments, the invention provides bisubstrate analog inhibitors of ghrelin O-acyltransferase, which can be effective in treating, for example, obesity and diabetes mellitus.Type: GrantFiled: September 18, 2009Date of Patent: July 8, 2014Assignee: The Johns Hopkins UniversityInventors: Philip A. Cole, Bradley P. Barnett, Yousang Hwang, Jef D. Boeke
-
Patent number: 8772228Abstract: The present invention relates to nanofibers. In particular, the present invention provides aligned nanofiber bundle assemblies. In some embodiments, the aligned nanofiber bundle assemblies are used for tissue regeneration, controlled growth of cells, and related methods (e.g., diagnostic methods, research methods, drug screening).Type: GrantFiled: February 14, 2008Date of Patent: July 8, 2014Assignee: Northwestern UniversityInventors: Samuel I. Stupp, Shuming Zhang, Alvaro Mata, Megan A Greenfield
-
Patent number: 8772449Abstract: A cell-penetrating peptide of (A) to (D) below gives cell membrane permeability and transmucosal absorbability to a physiologically active substance: (A) a peptide having the amino acid sequence of SEQ ID NO:1; (B) a peptide represented by SEQ ID NO:1 except that one or several basic amino acids are changed; (C) a peptide represented by SEQ ID NO:1 except that 1 to 5 amino acids are changed; (D) a peptide having: the reverse sequence of any of (A) to (C); an amino acid sequence which is the same as the reverse sequence of (A) except that one or several basic amino acids are changed; or an amino acid sequence which is the same as the reverse sequence of (A) except that 1 to 5 amino acids are changed.Type: GrantFiled: May 19, 2010Date of Patent: July 8, 2014Assignee: Toray Industries, Inc.Inventors: Mariko Morishita, Kozo Takayama, Reiji Nishio, Nobuo Ida
-
Publication number: 20140186379Abstract: The present invention discloses novel macromolecule transduction domain (MTD) peptides which facilitate the traverse of a biologically active molecule across the cell membrane. Also disclosed are polynucleotides encoding the MTD peptides, methods of identifying the MTD peptides; methods of genetically engineering a biologically active molecule to have cell permeability by using the MTD peptides, methods of importing a biologically active molecule into a cell by using the MTD peptides, and uses thereof.Type: ApplicationFiled: November 27, 2013Publication date: July 3, 2014Applicant: PROCELL THERAPEUTICS INC.Inventors: Dae Woong JO, Jae Sun Ko, Jin Sook Kim, Kyung Mi Park, Jin Kyung Song, Jung Hee Lim, Thi Thuy Nga Do, Thi Lan Phuong Do, Minh Tam Duong
-
Publication number: 20140186372Abstract: The invention relates to compositions, methods and uses of inhibitors of binding between PKC? and CD28, and modulating an undesirable or aberrant immune response, disorder or disease, an inflammatory response, disorder or disease, inflammation or an autoimmune response, disorder or disease. Compositions include inhibitors of binding between PKC? and CD28, which include, among others, PKC?, CD28 and Lck sequences, subsequences, variants and modified forms, and polymorphisms.Type: ApplicationFiled: June 15, 2012Publication date: July 3, 2014Applicant: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGYInventors: Amnon Altman, Kok-Fai Kong
-
Publication number: 20140187494Abstract: The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, inhibit the interaction of MUC1 with NF-?B or a STAT, and block inflammatory response mediated by NF-?B or STAT signaling.Type: ApplicationFiled: December 23, 2013Publication date: July 3, 2014Applicants: GENUS ONCOLOGY, LLC, DANA-FARBER CANCER INSTITUTE, INC.Inventors: Donald W. KUFE, Surender KHARBANDA
-
Patent number: 8765687Abstract: This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.Type: GrantFiled: October 17, 2006Date of Patent: July 1, 2014Assignee: Sloan Kettering Institute for Cancer ResearchInventors: David A. Scheinberg, Javier Pinilla-Ibarz, Rena May
-
Patent number: 8765686Abstract: Isolated polypeptides that recognize and are strong binders to Influenza A hemagglutinin and can be used, for example, to treat and/or limit development of an influenza infection, or to diagnose or monitor progression of an influenza infection are described.Type: GrantFiled: August 3, 2011Date of Patent: July 1, 2014Assignee: University of Washington through its Center for CommercializationInventors: David Baker, Timothy A. Whitehead, Sarel Fleishman
-
Patent number: 8765673Abstract: The present invention provides methods for promoting wound healing and/or reducing scar formation, by administering to an individual in need thereof one or more of the heat shock protein 20-derived polypeptides disclosed herein.Type: GrantFiled: January 4, 2012Date of Patent: July 1, 2014Assignee: Arizona Board of RegentsInventors: Colleen Brophy, Alyssa Panitch, Catherine Parmiter, Elizabeth Furnish, Padmini Komalavilas
-
Patent number: 8765688Abstract: The present invention relates to the use of special peptides in composition which can be used in particular in hair and skin cosmetics, and to such peptide-containing compositions. In particular, the present invention relates to the use of such peptides as active ingredient for inhibition or treatment of dandruff which does not accumulate in the body or in the environment. Furthermore, the invention relates to the production of such compositions, to the peptides used themselves, to their production and to coding nucleotide sequences for such peptides, to dispensing systems for such peptides and to screening methods for identifying suitable further peptides.Type: GrantFiled: December 19, 2008Date of Patent: July 1, 2014Assignee: BASF SEInventors: Burghard Liebmann, Heike Brüser, Heiko Barg, Daniel Hümmerich, Hubertus Peter Bell
-
Publication number: 20140179608Abstract: Described herein are methods to bind a compound to the SH2 domain of Src in a Src-expressing cell which includes contacting a compound comprising an amino acid compound to a Src-expressing cell; and binding a compound to the SH2 domain of Src.Type: ApplicationFiled: February 26, 2014Publication date: June 26, 2014Applicant: THE UNIVERSITY OF TOLEDOInventors: Zi-Jian Xie, Qiqi Ye, Zhichuan Li
-
Publication number: 20140179607Abstract: The present invention provides peptides that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms.Type: ApplicationFiled: November 9, 2010Publication date: June 26, 2014Applicant: IRONWOOD PHARMACEUTICALS, INCInventors: Mark G. Currie, Angelika Fretzen, Marco Kessler, Daniel P. Zimmer
-
Patent number: 8759300Abstract: Described herein are fragments of fibronectin and vitronectin and variants thereof that have certain activities, including growth factor-binding activity. Also described are fragments of growth factors that bind to fibronectin and inhibit binding of full-length growth factors to fibronectin. Compositions containing such fragments are useful in cosmetic treatments (e.g., the treatment of wrinkles or UV photodamage of skin), and the treatment of wounds and cancer.Type: GrantFiled: June 16, 2008Date of Patent: June 24, 2014Assignee: The Research Foundation for the State University of New YorkInventor: Richard A. Clark
-
Patent number: 8754049Abstract: A cyclic organic compound which comprises 16 amino acids or 17 amino acids and has no carboxyl group C-terminally and/or no amino group N-terminally. Optionally, one of the amino acids is a nonnatural amino acid. The ring closure is formed between a side chain of one amino acid and the C-terminus of another amino acid, or the ring closure is effected with the aid of a nonnatural amino acid. A process for producing and using the compound for regulating vectorial ion channels, for treating diseases associated with the lung function and for treating oedemas is provided.Type: GrantFiled: January 12, 2011Date of Patent: June 17, 2014Assignee: APEPTICO Forschung und Entwicklung GmbHInventors: Bernhard Fischer, Rudolf Lucas, Susan Tzotzos
-
Patent number: 8754047Abstract: The present invention provides isolated peptides with at least two cysteine residues capable of forming one or more disulfide bonds. Pharmaceutical compositions comprising the isolated peptides of the present invention are also provided. The invention also provides methods for inhibiting, preventing or improving the pathological or clinical manifestations of cancer or an inflammatory disease or disorder in a subject, comprising administering a peptide of the invention.Type: GrantFiled: January 27, 2011Date of Patent: June 17, 2014Assignee: The Research Foundation for the State University of New YorkInventors: Basil Rigas, Yu Sun
-
Publication number: 20140162961Abstract: Compositions and methods are provided including a transporter peptide derived from the loop2 domain of the neuronally-derived lynx1 protein which can be conjugated to an effector agent to form a transporter-effector complex for transport of the therapeutic effector agent to a target that is found across the blood brain barrier.Type: ApplicationFiled: December 9, 2013Publication date: June 12, 2014Applicant: OPHIDION INC.Inventor: Andreas Walz
-
Publication number: 20140162938Abstract: Peptide compounds based on the CAP37 protein are disclosed, along with methods for treating various infections, wounds, and conditions, and methods of promoting healing and acceptance of grafts, using compositions containing these peptides.Type: ApplicationFiled: December 3, 2013Publication date: June 12, 2014Applicant: The Board of Regents of the University of OklahomaInventor: Heloise Anne Pereira
-
Patent number: 8748394Abstract: A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a synthetic apolipoprotein A-1 (Apo A-I) mimetic peptide into a wall of the blood vessel at the particular region, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including a synthetic apolipoprotein A-I (Apo A-I) mimetic peptide, or combination of an Apo A-I synthetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of an endogenous Apo A-I related peptide. A composition including an apolipoprotein A-1 (Apo A-I) synthetic peptide in a form suitable for delivery into a blood vessel, the peptide including an amino acid backbone that has less amino acid residues relative to endogenous Apo A-I and a chimera of helix 1 and helix 9 of Apo A-I.Type: GrantFiled: February 22, 2013Date of Patent: June 10, 2014Assignee: Abbott Cardiovascular Systems Inc.Inventors: Katsuyuki Murase, Li Zhao, Irina Astafieva, Paul M. Consigny
-
Patent number: 8748397Abstract: Lyophilized pulmonary surfactants having an increased specific surface area and porosity are described. Methods of making the lyophilized pulmonary surfactants are also described.Type: GrantFiled: November 27, 2013Date of Patent: June 10, 2014Assignee: Discovery Laboratories, Inc.Inventors: Sergio Cesco-Cancian, Thomas Hoy, Edward H. Trappler, Michael S. Thomas
-
Patent number: 8748389Abstract: The present invention provides a peptide comprising an amino acid sequence that is part of the amino acid sequence of CDK4 protein, or homologous to part of the amino acid sequence of CDK4 protein, which peptide is cytotoxic to, and/or inhibiting to the growth of, a cancer cell and/or stimulating to the growth of a non-cancerous cell and/or a control cell. Methods of identifying such peptides and medical uses of such peptides are also disclosed.Type: GrantFiled: June 14, 2005Date of Patent: June 10, 2014Assignee: Theryte LimitedInventors: Hilmar Meek Warenius, Jonathan Essex, Jeremy Kilburn
-
Patent number: 8748395Abstract: Protein kinase inhibitors and more specifically inhibitors of the protein kinase c-Jun amino terminal kinase are described. Additionally, JNK inhibitor sequences, chimeric peptides, nucleic acids encoding same as well as pharmaceutical compositions for treating pathophysiologies associated with JNK signaling are described.Type: GrantFiled: September 12, 2006Date of Patent: June 10, 2014Assignee: Xigen Inflammation Ltd.Inventor: Christophe Bonny
-
Patent number: 8748396Abstract: Lyophilized pulmonary surfactants having an increased specific surface area and porosity are described. A method of making lyophilized pulmonary surfactants is described.Type: GrantFiled: November 27, 2013Date of Patent: June 10, 2014Assignee: Discovery Laboratories, Inc.Inventors: Sergio Cesco-Cancian, Thomas Hoy, Edward H. Trappler, Michael S. Thomas
-
Patent number: 8741849Abstract: The present invention relates to kinase inhibiting compositions and uses thereof. The invention further provides isolated kinase inhibiting peptides and uses thereof for inhibiting hyperplasia, for inhibiting the growth of neoplasms, and for inducing programmed cell death in a cell population.Type: GrantFiled: August 7, 2008Date of Patent: June 3, 2014Assignee: Purdue Research FoundationInventors: Alyssa Panitch, Brandon Seal, Brian Ward